Evidence map›Paper›PMID 41894083›Full record

ReviewMedScience2026

High-altitude exposure remodels the gut microbiota: health and disease.

Yan Li, Mingshan Jiang, Jiangmei Pang, Chunxiang Ma, Hong Zhang, Fang Yin, Yongbin Jia, Xiang Zou, Tao Zuo, Hu Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in MedScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yan Li *Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Mingshan Jiang *Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jiangmei PangDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Chunxiang MaDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Hong ZhangDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Fang YinDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yongbin JiaLab of Inflammatory Bowel Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610200, China.
Xiang ZouDepartment of Health Technology and Informatics, Hong Kong Polytechnic University, Hong Kong, 999077, China.
Tao ZuoKey Laboratory of Human Microbiome and Chronic Diseases, Sun Yat-sen University, Ministry of Education, Guangzhou, 510655, China. zuot@mail.sysu.edu.cn.
Hu ZhangDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041, China. zhanghu@scu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the increasing number of individuals travelling to or residing in high-altitude regions, understanding the physiological and pathological consequences of such environments has become increasingly important. High-altitude exposure poses significant challenges to human health, primarily due to hypobaric hypoxia, which triggers a cascade of responses, including energy deficiency, oxidative stress, and inflammation. One of the critical consequences is the disruption of the gut barrier, which facilitates the translocation of the gut microbiota and further exacerbates local and systemic inflammation. Notably, the gut microbiota, a dynamic environmental sensor, undergoes significant remodelling in high-altitude environments. The modified production of microbial metabolites such as bile acids influences gut homeostasis as well as glucose and lipid metabolism, and ultimately contributes to individual variability in high-altitude acclimatization. These changes have been implicated in the pathogenesis of altitude-related illnesses such as acute and chronic mountain sickness, as well as in metabolic and gastrointestinal disorders such as diabetes, obesity, irritable bowel syndrome, colorectal cancer, cholelithiasis, and osteoporosis. Preliminary explorations have demonstrated the therapeutic potential of microbiome-based interventions such as faecal microbiota transplantation in acute and chronic mountain sickness. Further research into gut microbiota modulation may provide applicable options for promoting high-altitude acclimatization and preventing high-altitude illness.

Indexed as

AltitudeAltitude SicknessGastrointestinal MicrobiomeAcclimatizationAnimalsHumansHypoxiaacclimatizationgut barriergut microbiotahypoxiamountain sickness

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.